For the second quarter of the fiscal year 2023, PUMA BIOTECHNOLOGY ($NASDAQ:PBYI) reported total revenue of USD 54.6 million, a decrease of 8.3% year-on-year. Net income for the same period dropped by 77.3% compared to the previous year, amounting to USD 2.1 million.
Analysis – Puma Biotechnology Stock Fair Value Calculation
GoodWhale has conducted an analysis of PUMA BIOTECHNOLOGY‘s wellbeing and conclude that the intrinsic value of its shares is around $4.8. This value was calculated using our proprietary Valuation Line, which takes into account a range of different metrics that show a company’s health and prospects. Currently, PUMA BIOTECHNOLOGY stock is trading at $3.5, which is 27.1% lower than the intrinsic value, making it an attractive investment option for investors who are looking for a good return. As such, while the stock may have been undervalued in the past, this analysis shows that now is the time to take advantage of the favourable price. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Puma Biotechnology. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Puma Biotechnology. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Puma Biotechnology. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Puma Biotechnology are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The biopharmaceutical industry is highly competitive, with companies vying for market share in the development and commercialization of innovative therapies. In the field of cancer treatment, Puma Biotechnology Inc has emerged as a leader, with its groundbreaking therapy neratinib (Nerlynx) approved for the treatment of HER2-positive breast cancer. However, the company faces stiff competition from Genmab A/S, UroGen Pharma Ltd, and Mesoblast Ltd, all of which are developing their own innovative cancer therapies.
Genmab A/S is a publicly traded Danish biotechnology company. As of May 2020, it had a market capitalization of US$18.38 billion. The company focuses on the development and commercialization of innovative antibody-based therapies for the treatment of cancer and other serious diseases. Genmab’s portfolio includes two commercially available products, Darzalex (daratumumab) and Arzerra (ofatumumab), and a broad pipeline of antibody-based therapeutics in clinical and pre-clinical development.
UroGen Pharma Ltd is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies to treat urological conditions. The company’s products include UroLift System, a minimally invasive treatment for enlarged prostate, and VESIcare, a treatment for overactive bladder.
UroGen Pharma’s market cap is 269.93M as of 2022. The company has a Return on Equity of 191.74%.
The company’s products are designed to improve the lives of patients suffering from urological conditions. The company’s products are backed by clinical data and have the potential to change the standard of care for urological conditions.
– Mesoblast Ltd ($ASX:MSB)
Mesoblast Limited is a global leader in the development and commercialization of innovative cellular medicines. The company has a diversified portfolio of products in clinical and commercial stages. Mesoblast’s products are based on its proprietary mesenchymal lineage adult stem cell technology.
Mesoblast has a market capitalization of 732.9 million as of 2022 and a return on equity of -9.2%. The company’s products are based on its proprietary mesenchymal lineage adult stem cell technology. Mesoblast is a global leader in the development and commercialization of innovative cellular medicines.
PUMA BIOTECHNOLOGY has reported a decline in its second quarter earnings for fiscal year 2023. Total revenue was down 8.3% compared to the previous year, while net income was down 77.3%. This could be an indication of a less-than-ideal investment opportunity for potential investors. It is important to conduct research and analysis to determine whether the current market conditions and the company’s financial performance are likely to improve over time, and whether PUMA BIOTECHNOLOGY may be a good fit for your portfolio.